Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
A Phase II Study of Efficacy, Toxicity, and the Potential Impact of Genomic Alterations on Response to Eribulin Mesylate in Combination With Trastuzumab and Pertuzumab in Women With Human Epidermal Growth Factor Receptor 2 (HER2)+ Metastatic Breast CancerBreast Cancer Res Treat 2021 Jul 24;[EPub Ahead of Print], SM Balch, I Vaz-Luis, T Li, N Tayob, E Jain, K Helvie, JE Buendia-Buendia, E Shannon, SJ Isakoff, NM Tung, IE Krop, NU Lin, N Wagle, RA Freedman
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.